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Abstract
Background: Severe alpha1-antitrypsin (AAT) deficiency is a strong risk factor for COPD. But the impact of gene variants
resulting in mild or intermediate AAT deficiency on the longitudinal course of respiratory health remains controversial.
There is indication from experimental studies that pro-inflammatory agents like cigarette smoke can interact with these
variants and thus increase the risk of adverse respiratory health effects. Therefore, we tested the effect of the presence of a
protease inhibitor (Pi) S or Z allele (PiMS and PiMZ) on the change in lung function in different inflammation-exposed
subgroups of a large, population-based cohort study.
Methodology and Principal Findings: The SAPALDIA population includes over 4600 subjects from whom SERPINA1
genotypes for S and Z alleles, spirometry and respiratory symptoms at baseline and after 11 years follow-up, as well as
proxies for inflammatory conditions, such as detailed smoking history, obesity and high sensitivity C-reactive protein (hs-
CRP), were available. All analyses were performed by applying multivariate regression models. There was no overall
unfavourable effect of PiMS or PiMZ genotype on lung function change. We found indication that PiZ heterozygosity
interacted with inflammatory stimuli leading to an accelerated decline in measures in use as indices for assessing mild
airway obstruction. Obese individuals with genotype PiMM had an average annual decline in the forced mid expiratory flow
(DFEF25-75%) of 58.4 ml whereas in obese individuals with PiMZ it amounted to 92.2 ml (p = 0.03). Corresponding numbers
for persistent smokers differed even more strongly (66.8 ml (PiMM) vs. 108.2 ml (PiMZ), p = 0.005). Equivalent, but less strong
associations were observed for the change in the FEV1/FVC ratio.
Conclusions: We suggest that, in addition to the well established impact of the rare PiZZ genotype, one Z allele may be
sufficient to accelerate lung function decline in population subgroups characterized by elevated levels of low grade
inflammation.
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Introduction
Reduced lung function measures are the most common
diagnostic parameter to detect airway obstruction which is the
main characteristic of asthma and chronic obstructive pulmonary
disease (COPD). The only functionally characterized gene variants
associated with airway obstruction and increased loss of lung
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function are infrequent polymorphisms in the SERPINA1 gene
causing deficiency of alpha1-antitrypsin (AAT) [1]. This antipro-
tease inhibits neutrophil elastase, an enzyme that degrades
pulmonary elastic fibers. Homozygosity for the protease inhibitor
deficiency variant Z (PiZZ, also referred to as severe AAT
deficiency) and compound heterozygosity for both deficiency
variants S and Z (PiSZ) are widely accepted risk factors for airway
obstruction and accelerated lung function decline, particularly
among smokers [2]. But since these allele combinations all have
frequencies below 0.1% in the general European population [3],
they only account for 2-5% of all COPD cases. The more
prevalent heterozygous genotypes PiMS and PiMZ (M stands for
the wildtype allele) reduce the AAT blood levels only slightly [4]
and are therefore referred to as mild (for PiMS) and intermediate
(for PiMZ) AAT deficiencies.
While PiMS is generally believed not to be associated with low
lung function or a higher risk of COPD [5], the evidence for PiMZ
remains unclear even in the light of a meta-analysis [6]. The few
population-based longitudinal studies have not shown adverse
health effects, but they varied with regard to the phenotype studied
and the inclusion of gene-environment interactions [7,8,9]. An
investigation restricted to smokers showed that PiMZ was
overrepresented in the group with rapid FEV1 (forced expiratory
volume in one second) decline, suggesting that susceptibility may
be refined to population subgroups with elevated inflammatory
and proteolytic stress in the lungs [10]. These processes may
locally increase cleavage, as well as oxidant-induced inactivation
[11] and polymerization [12] of AAT, leading to a further
reduction of this enzyme in PiMZ carriers. Apart from inhalant
triggers like smoking, systemic inflammation may also compromise
pulmonary health [13,14] and therefore particularly affect
individuals with reduced AAT levels.
We hypothesized therefore that the intrapulmonary anti-
proteolytic capacity in people with mild or intermediate AAT
deficiency may not be sufficient to counterbalance an excess of
inflammatory triggers targeting the respiratory system. We used
the SAPALDIA cohort (Swiss Cohort Study on Air Pollution and
Lung and Heart Diseases in Adults) to test such possibly
unfavourable effects of PiS or PiZ heterozygosity on the
longitudinal course of lung function over 11 years of follow-up
in the general population. The large and well characterized study
population allowed us to particularly study subgroups exposed to
elevated local airway or systemic inflammatory conditions, such as
active and passive smokers, and people suffering from obesity.
Results
Study Sample
A comparison of characteristics between SAPALDIA follow-up
participants included and excluded in this study is provided in
Table 1. The study population consisted of a healthier sample with
a higher percentage of never-smokers and fewer obese individuals.
A comparison between the three genotype classes showed highly
significant differences in AAT serum levels (Table 1). Compared to
PiM homozygotes, unadjusted AAT serum concentrations were
more than 16% and 38% reduced in PiS and PiZ heterozygotes,
respectively. There were no differences in circulating high-
sensitivity C-reactive protein (hs-CRP), the main marker for
systemic inflammation, between the genotype groups. Further-
more, the genotype classes differed slightly in the unadjusted
forced expiratory flow over the middle half of FVC (FEF25-75%)
at baseline and in unadjusted declines of FEF25-75%.
Adjusted Spirometric Decline Rates according to
Genotype
In adjusted models, neither PiMS nor PiMZ subjects exhibited
statistically significant steeper annual declines than PiMM
individuals in any measure of lung function (all p$0.07, Table 2
and Table 3). Hypothesizing that PiMS and PiMZ carriers can
only compensate their reduced anti-proteolytic capacity in
pulmonary tissue if no excess of pulmonary or systemic
inflammation is present, we tested if stratification by smoking or
obesity status may alter these associations. While we could not find
any significant association between the presence of a S or Z allele
and DFEV1 or DFVC (forced vital capacity) irrespective of the
smoking or obesity category (Table 2), smokers and obese
individuals with PiMZ genotype showed elevated declines in
FEF25-75% (Table 3). In ever smokers, PiMZ carriers lost on
average additional 17.4 ml per year compared to PiMM in FEF25-
75% (p= 0.05), and this difference became more pronounced in
people who smoked at baseline and follow-up (41.4 ml in persistent
smokers, p = 0.005). A similar pattern could be observed in obese
participants (DFEF25-75%=58.4 ml (PiMM) vs. 92.2 ml (PiMZ),
p = 0.03). There was no such effect in never-smokers exposed to
environmental tobacco smoke. Values for D (FEV1/FVC)
consistently confirmed this trend, but associations did not reach
statistical significance. For DFEF25-75%, the presence of a Z allele
interacted statistically significant with smoking (pinteraction = 0.04
with smoking status (persistent vs. never) and pinteraction = 0.002
with packyears between the two surveys), but not with obesity
status (p = 0.14). Statistically significant modification of the Z allele
effect on D (FEV1/FVC) could be observed for packyears between
the two surveys and obesity status (pinteraction = 0.04 and 0.08,
respectively). As we had previously found sex differences in the
association between circulating AAT concentrations and lung
function [15], we further evaluated a possible effect modification
by sex. However, sex did not significantly modify the allele effect
on any lung function measure (all pinteraction $ 0.15).
High-sensitivity C-reactive Protein (hs-CRP) as a Proxy for Low
Systemic Inflammation
In order to strengthen the hypothesis that low grade systemic
inflammation drove the observed Z allele effect on pulmonary
function, we investigated the associations in participants with
elevated hs-CRP levels at follow-up (defined as the upper tertile of
the study population, i.e.$1.8 mg/l). Consistent with our findings
for smokers and obese people, declines in PiZ heterozygotes were
significantly enhanced for FEF25-75% (99.3 ml (PiMZ) vs. 71.2 ml
(PiMM), p = 0.006) and suggestively for FEV1/FVC (5.46%
(PiMZ) vs. 4.00% (PiMM), p= 0.07) (Table 3), but not for FEV1
or FVC. Interestingly, also PiS heterozygotes in the upper tertile of
hs-CRP values showed statistically significant larger declines in
FEF25-75% (p= 0.003) and FEV1/FVC (p= 0.04) than PiMM
subjects.
Incidence of Airway Obstruction and Respiratory
Symptoms
As a next step we tried to expand our analyses on the change of
spirometry measures with clinically relevant outcomes like the
incidence of airway obstruction or the development of respiratory
symptoms. 103 PiMZ carriers did not show airway obstruction at
baseline which was defined by FEV1/FVC , 0.7. In 17 of them a
smaller ratio than 0.7 was calculated at follow-up, which classified
them as incident cases. Comparing with PiMM individuals this
resulted in an adjusted odds ratio of 1.11 (95% CI= 0.64 to 1.93,
p = 0.70; Table 4). Corresponding investigations with individuals
exposed to elevated inflammatory conditions did not show an
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increased obstruction risk for Z heterozygotes, but were based on
very few numbers of cases. As far as the development of
respiratory symptoms like regular cough, phlegm or shortness of
breath during sleep was concerned, there seemed to be a trend
that PiMZ individuals were more susceptible than PiMM carriers,
in particular in subgroups exposed to pro-inflammatory conditions
(Table 4). But the limited statistical power did unfortunately not
allow a comprehensive evaluation of our hypothesis.
Validity
As chronic asthma is suggested to be associated with accelerated
loss of pulmonary function [16] and in the absence of post-
bronchodilation spirometry, we conducted a sensitivity analysis by
including only subjects who did not report physician-diagnosed
asthma. Furthermore, level of lung function change in adults is
also determined by lung function growth during early adulthood,
and to account for that, we performed another sensitivity analysis
by only including participants older than 30 years of age at
baseline. Neither of the two restrictions did essentially alter the
results (Table S1).
Replacing the change of FEF25-75% by the change of the ratio
FEF25-75%/FVC led to very similar conclusions (Table S2).
Finally, in order to detect potential participation bias, we weighted
each observation inverse to the probability of being included in the
study sample. None of the results of the regression analyses did
materially change (Table S3).
Discussion
In the present study, neither PiS nor PiZ heterozygosity
influenced longitudinal lung function measured by DFEV1 or
DFVC, independent of smoking or obesity status. However, PiMZ
genotype was associated with an accelerated FEF25-75% decline
in smoking and obesity subgroups from the general population.
Results for participants in the upper tertile of hs-CRP values
strengthened the notion that PiMZ carriers might be more
susceptible to systemic pro-inflammatory conditions with respect
to lung function parameters indicating narrowing of small airways.
Table 1. Characteristics of SAPALDIA follow-up participants at baseline (1991; upper part), follow-up (2002; middle part), and
between the two examinations (lower part).
Not included in Study
(N=3372)
Included in Study
(N=4675) PiMM (N=4207) PiMS (N=356) PiMZ (N=112) P-valuea
At baseline
% women 51.2 52.4 52.6 50.8 53.6 0.80
Age (y), median, IQR 42.4 (32.6, 51.1) 41.4 (31.7, 49.7) 41.5 (31.6, 49.8) 41.3 (32.9, 49.6) 38.3 (31.3, 47.3) 0.33
% never smokers 39.9 (N = 3360) 49.6 49.3 51.7 54.5 0.39
% current smokers 34.9 (N = 3360) 29.6 30.0 27.2 24.1 0.24
% ETS in never smokers 30.6 (N = 1340) 28.3 (N = 2318) 28.5 (N = 2073) 24.5 (N = 184) 34.4 (N = 61) 0.29
BMI (kg/m2), median, IQR 23.7 (21.3, 26.3; N = 3306) 23.1 (21.1, 25.6) 23.1 (21.0, 25.7) 23.3 (21.2, 25.7) 22.9 (21.3, 24.9) 0.80
% obeseb 7.6 (N = 3306) 5.3 5.4 4.5 4.5 0.72
FEV1 (mL), mean6SD 34856864 (N = 2910) 35766824 35706825 36176819 3627 6 787 0.35
FVC (mL), mean6SD 441561062 (N = 2929) 452761022 452261025 458061000 45536987 0.57
FEF25-75% (mL), mean6SD 337161228 (N = 2794) 343661223 342661221 346861212 370661320 0.05
FEV1/FVC (%), mean6SD 79.1067.93 (N = 2794) 79.2167.59 79.1867.56 79.0767.83 80.6168.01 0.14
At follow-up
% never smokers 40.7 (N = 2936) 48.1 47.8 49.7 53.6 0.40
% current smokers 32.3 (N = 2936) 22.6 22.8 21.9 16.1 0.23
% ETS in never smokers 15.1 (N = 1189) 15.4 (N = 2249) 15.5 (N = 2012) 14.7 (N = 177) 15.0 (N = 60) 0.96
BMI (kg/m2), median, IQR 25.7 (23.0, 28.8; N = 1923) 25.2 (22.7, 28.2) 25.2 (22.7, 28.2) 25.4 (22.8, 28.4) 25.2 (23.1, 27.6) 0.88
% obeseb 18.1 (N = 1923) 15.2 15.2 15.2 14.3 0.96
AAT (g/L), mean6SD 1.2560.22 (N = 1642) 1.2760.20 1.3060.19 1.0960.16 0.8060.11 ,0.001
hs-CRP (mg/L), median, IQR 1.1 (0.5, 2.3; N = 1642) 1.0 (0.5, 2.3) 1.0 (0.5, 2.3) 1.0 (0.5, 2.0) 0.9 (0.5, 2.5) 0.16
Between baseline and follow-up
DFEV1 (mL/y), mean6SD -35.2632.6 (N = 1278) -35.3629.8 -35.1629.8 -37.7630.1 -36.3628.7 0.27
DFVC (mL/y), mean6SD -26.1643.7 (N = 1266) -24.1640.2 -24.1640.2 -25.0639.7 -22.4641.5 0.82
DFEF25-75% (mL/y), mean6SD -64.2664.1 (N = 1070) -71.1665.2 -70.4664.8 -76.0664.9 -84.3677.9 0.03
D (FEV1/FVC) (%/y), mean6SD -3.4965.19 (N = 1071) -4.0564.95 -4.0164.94 -4.2665.01 -4.6264.99 0.32
AAT: Alpha1-antitrypsin; BMI: Body mass index; ETS: regularly exposed to environmental tobacco smoke; FEF25-75%: mid expiratory flow; FEV1: forced expiratory
volume in 1 second; FVC: forced vital capacity; hs-CRP: high-sensitivty C-reactive protein; IQR: Interquartile range; SD: Standard deviation.
aPearson’s x2 test for testing equal proportions, analysis of variance (ANOVA) for testing equal means of normally distributed data (AAT levels and spirometric
measurements), and Kruskal-Wallis test for testing equal distributions in not normally distributed data (age and BMI values) between the three genotype classes.
bObese subjects were defined as having a BMI$30kg/m2.
doi:10.1371/journal.pone.0042728.t001
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The Role of Smoking and Pulmonary Oxidative Stress
It is well established that smokers suffering from severe AAT
deficiency, a condition accompanied by only 15% of normal AAT
blood concentrations, are particularly vulnerable to developing
early onset COPD [2]. There is less evidence that intermediate or
even mild AAT deficiency modify the effect of smoking or other
oxidative inhalants on lung function. In a small study of 56-year-
old men, a higher mean annual decrease in FEV1 in smoking
PiMZ individuals was reported as compared with non-smoking
PiMZ or smoking PiMM individuals [17], but larger studies could
not find such an interaction [7,9]. Results of studies investigating
the impact of environmental and occupational exposure are
heterogeneous [18]. Passive smoking has been shown in school
children to be associated with cross-sectional lower lung function
only in children having low levels of AAT in the blood, and
particularly in measures of mid- to end-expiratory flow rates [19].
A recent longitudinal study found accelerated lung function
declines in New York City firefighters of PiMZ genotype
compared to PiMM in the years after World Trade Center
collapse accompanied by massive air pollution, and no such
difference could be observed prior to September 11, 2001 [20].
Support for a gene-environment interaction comes also from
genome-wide as well as from experimental studies. While genome-
wide association studies on COPD and lung function have not
found the SERPINA1 locus among the top hit signals [21,22,23], it
was the most strongly associated candidate gene in ever smokers in
a comprehensive evaluation of potential lung function associated
genes in more than 20,000 individuals from the general population
[24]. Oxidation of the Z form by cigarette smoke induced its
polymerization in lung tissue of transgenic PiZZ mice [12]. Such
polymers could also be detected on the lung surface in human PiZ
homozygotes, originating either from lung epithelial cells or
macrophages and independent of the main hepatocytic secretion
[25]. In addition to being an ineffective elastase inhibitor, these
polymers attracted a higher number of neutrophils, further shifting
the protease-antiprotease equilibrium towards proteolysis. As
subjects with PiMZ genotype also exhibit elevated levels of
intrapulmonary neutrophilic inflammation [26], they are poten-
tially more susceptible to oxidative inhalants. The observed dose-
response trend in the interaction between smoking and the
presence of a Z allele is in agreement with this biological concept.
The Role of Obesity and Systemic Low Grade
Inflammation
The observed accelerated loss of pulmonary function in obese
subjects carrying the PiMZ genotype is novel. The often observed
inverse association between obesity and lung function is in part
explained by a mechanical effect of obesity on lung volume and
airway caliber. Yet more limited evidence suggests an additional
effect of obesity on peripheral airway obstruction that may be
related to systemic low grade inflammation [27]. Adipose tissue
from subjects who are overweight or obese produces pro-
inflammatory adipokines that spill over to the blood stream.
Elevated circulating concentrations of inflammation markers such
Table 2. Adjusted mean values in DFEV1 and DFVC over 11 years of follow-up comparing different SERPINA1 genotypes.
DFEV1(ml/y) 95%CI P-value DFVC(ml/y) 95%CI P-value
Total
PiMM, N= 4207 -35.2 -36.0 to -34.4 -24.1 -25.2 to -23.0
PiMS, N = 356 -36.9 -39.7 to -34.1 0.24 -24.7 -28.3 to -21.0 0.77
PiMZ, N= 112 -36.0 -41.0 to -31.1 0.74 -23.3 -29.8 to -16.7 0.80
Passive Smokersa
PiMM, N= 691 -32.3 -34.5 to -30.2 -21.4 -24.1 to -18.6
PiMS, N = 52 -33.9 -41.5 to -26.3 0.69 -26.3 -35.9 to -16.7 0.33
PiMZ, N= 22 -41.3 -52.9 to -29.7 0.14 -34.5 -49.2 to -19.7 0.09
Ever Smokers
PiMM, N= 2194 -35.1 -36.4 to -33.8 -25.0 -26.7 to -23.2
PiMS, N = 179 -36.8 -40.8 to -32.7 0.43 -24.1 -29.5 to -18.6 0.75
PiMZ, N= 52 -35.4 -42.8 to -27.9 0.94 -21.6 -31.6 to -11.6 0.51
Persistent Smokersb
PiMM, N= 922 -35.6 -39.3 to -31.9 -26.6 -31.3 to -21.9
PiMS, N = 74 -41.7 -48.7 to -34.8 0.07 -30.6 -39.4 to -21.7 0.35
PiMZ, N= 18 -41.2 -54.5 to -27.9 0.40 -24.0 -40.8 to -7.1 0.75
Obese subjectsc
PiMM, N= 653 -36.8 -42.4 to -31.3 -33.6 -41.1 to -26.1
PiMS, N = 55 -37.1 -46.3 to -28.0 0.94 -29.7 -42.1 to -17.4 0.48
PiMZ, N= 16 -48.0 -62.9 to -33.1 0.12 -34.7 -54.8 to -14.6 0.91
CI: confidence interval. FEV1: forced expiratory volume in 1 second. FVC: forced vital capacity.
Covariates included sex, linear and squared age, recruiting area, smoking history (packyears at baseline, as well as linear and squared packyears between baseline and
follow-up), height, baseline BMI and BMI change between baseline and follow-up.
aPassive smokers were defined as never smokers who declared regular exposure to environmental tobacco smoke within one year prior to the baseline or follow-up
examination.
bPersistent smokers were classified as subjects who declared current smoking at both examinations.
cObese subjects were defined as BMI$30kg/m2 at the baseline or follow-up examination.
doi:10.1371/journal.pone.0042728.t002
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as hs-CRP or interleukin-6 (IL-6) are both, higher in obese persons
[28,29] and associated with accelerated lung function decline
[30,31]. Also in the SAPALDIA cohort, we have previously
reported that accelerated lung function decline and obesity are
both associated with increased hs-CRP, particularly in women
[32]. Mendelian randomization approaches to examine causality
between increased hs-CRP and lower respiratory function led to
conflicting results [30,33]. However, these studies did not assess
the effect of CRP gene variants on lung function separately in
groups exposed to pro-inflammatory agents such as smokers.
This Study in Context
A longitudinal study in smokers reported an overrepresentation
of PiMZ participants in rapid lung function decliners [10].
However, population-based cohort studies did not find consistent
PiMZ effects on lung function decline, neither generally, nor in
smoking strata [7,8,9]. The only marginally statistical significant
result was found in non-smoking PiMZ carriers who showed a
steeper unadjusted lung function decline than non-smoking PiMM
subjects [7]. Our study was generally in good agreement with these
results as we could not detect any statistical significant effect of
SERPINA1 genotypes on DFEV1, which was the primary focus of
the previously mentioned studies. Compared to those existing
publications we included in our analysis a wider range of
spirometry measures and found associations with the decline of
FEF25-75% as well as weaker, but relatively consistent associations
with the decline of the FEV1/FVC ratio. Both these two measures
are in use to assess early airway obstruction and may probably best
reflect the volume of the small airways [34,35]. There are hardly
any large studies which used these measures in connection with
SERPINA1 genotypes so far, apart from a recent study of two large
populations that found PiMZ genotypes associated with lower
FEV1/FVC ratio and with more severe emphysema on chest
computer tomography scan, but not with COPD status [36]. Flow
related spirometric characteristics such as FEF25-75% may be
decreased in the presence of airway abnormalities including
inflammation or alterations in elastic recoil, two important
correlates of AAT deficiency [37]. For example, interactions
between glutathione S-transferase (GST) deficiency genotypes and
passive smoking were strongest for mid expiratory flow measures
Table 3. Adjusted mean values in D (FEV1/FVC) and DFEF25-75% over 11 years of follow-up comparing different SERPINA1
genotypes.
DFEF25-75%(ml/y) 95%CI P-value D (FEV1/FVC)(%/y) 95%CI P-value
Total
PiMM, N= 4207 -70.6 -72.5 to -68.7 -4.03 -4.17 to -3.89
PiMS, N = 356 -74.4 -80.8 to -68.0 0.26 -4.14 -4.62 to -3.66 0.65
PiMZ, N= 112 -81.4 -92.8 to -70.0 0.07 -4.46 -5.31 to -3.60 0.33
Passive Smokersa
PiMM, N= 691 -67.5 -72.4 to -62.5 -3.88 -4.23 to -3.53
PiMS, N = 52 -65.5 -82.8 to -48.3 0.84 -3.01 -4.23 to -1.79 0.18
PiMZ, N= 22 -65.8 -92.3 to -39.4 0.91 -3.11 -4.98 to -1.24 0.43
Ever Smokers
PiMM, N= 2194 -70.0 -73.0 to -67.1 -3.84 -4.06 to -3.62
PiMS, N = 179 -74.9 -84.2 to -65.6 0.32 -4.16 -4.85 to -3.47 0.38
PiMZ, N= 52 -87.4 -104.5 to -70.4 0.05 -4.80 -6.07 to -3.53 0.14
Persistent Smokersb
PiMM, N= 922 -66.8 -75.2 to -58.4 -3.90 -4.53 to -3.27
PiMS, N = 74 -74.0 -89.8 to -58.3 0.34 -4.62 -5.81 to -3.44 0.21
PiMZ, N= 18 -108.2 -138.1 to -78.2 0.005 -5.25 -7.51 to -2.99 0.23
Obese Subjectsc
PiMM, N= 653 -58.4 -70.1 to -46.7 -2.81 -3.70 to -1.93
PiMS, N = 55 -59.5 -78.8 to -40.1 0.90 -3.61 -5.07 to -2.15 0.22
PiMZ, N= 16 -92.2 -123.7 to -60.6 0.03 -5.13 -7.52 to -2.75 0.05
Subjects in upper tertile
of hs-CRPd
PiMM, N= 1387 -71.2 -74.8 to -67.6 -4.00 -4.28 to -3.71
PiMS, N = 99 -89.8 -102.0 to -77.7 0.003 -5.03 -5.99 to -4.06 0.04
PiMZ, N= 36 -99.3 -119.3 to -79.4 0.006 -5.46 -7.04 to -3.88 0.07
CI: confidence interval. FEF25-75%: forced mid expiratory flow. FEV1: forced expiratory volume in 1 second. FVC: forced vital capacity.
Covariates included sex, linear and squared age, recruiting area, smoking history (packyears at baseline, as well as linear and squared packyears between baseline and
follow-up), height, baseline BMI and BMI change between baseline and follow-up.
aPassive smokers were defined as never smokers who declared regular exposure to environmental tobacco smoke within one year prior to the baseline or follow-up
examination.
bPersistent smokers were classified as subjects who declared current smoking at both examinations.
cObese subjects were defined as BMI$30kg/m2 at the baseline or follow-up examination.
dCorresponded to a level of $ 1.8 mg/l.
doi:10.1371/journal.pone.0042728.t003
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in children [38]. However, these measures have often been
criticized for being more variable and therefore less reliable than
FEV1 [39]. We observed a correlation coefficient of 0.82 between
baseline and follow-up FEF25-75% in SAPALDIA which is
smaller than the one for FEV1 (0.92) and FVC (0.91), but larger
than the one for the more commonly used FEV1/FVC ratio
(0.74). Since we consistently found main and interacting effects of
air pollution strongest for this mid flow parameter [40,41,42], it
seems unlikely that the results of the present study are driven by
measurement error. Moreover, FEF25-75% was found to have a
high heritability in families with severe COPD [37].
Strengths and Weaknesses
The strength of this study is its large sample size, its detailed
characterization of subjects, and its stringent quality control of
spirometry [43]. The credibility of our results is supported by the
fact that the reduction of AAT serum levels in PiMS and PiMZ
compared to PiMM subjects was similar to that described by
others [7]. Compared to the hitherto existing publications, we
carefully excluded carriers of additional, rare mutations influenc-
ing AAT serum levels in order to diminish misclassification of
wildtype alleles.
Our study has some limitations. First, a possible selection of
healthy individuals may limit the generalizability of the results.
However, giving more weight to underrepresented groups within
the study sample did not alter the results. Moreover, if persons
with low levels of lung function were preferentially lost among
PiMZ carriers, stated effects may be an underestimation of the true
effect. Second, PiMZ individuals showed slightly higher baseline
FEF25-75% and FEV1/FVC values which can be partially
explained by the younger age and the reduced number of smokers
in this group, but which may question the clinical relevance of the
accelerated decline in these measures. Yet, the combination of a
higher level of cross-sectional lung function and a steeper lung
function decline after exposure to inflammatory agents parallels
observations in New York City firefighters before and after the
September 11 attacks [20]. Furthermore, spirometric measure-
ments were carried out without bronchodilator [44], which
hinders a clinically acceptable definition of airway obstruction.
Unlike some comparable studies [9,10], we performed spirometry
at only two time points. This makes our change values susceptible
to imprecision, but we do not expect substantial measurement
error for several reasons. The same spirometers and stringent
quality criteria at baseline and follow-up were applied, correlation
coefficients between the measurements at the two time points were
high, and the direction of most genotype effects were consistent for
all lung function outcomes. In addition, since it would be unlikely
that any measurement error is associated with the SERPINA1
genotype, misclassification would be non-differential, which
indicates an underestimation rather than an overestimation of
Table 4. Adjusted odds ratios for developing airway obstruction (FEV1/FVC,0.7) and respiratory symptoms over 11 years of
follow-up comparing different SERPINA1 genotypes.
Incidence of Airway Obstruction Incidence of Respiratory Symptoms
N (cases/total) OR 95%CI P-value N (cases/total) OR 95%CI P-value
Total
PiMM 601/3775 ref. 380/3547 ref.
PiMS 50/315 0.97 0.70 to 1.35 0.86 33/307 1.07 0.73 to 1.57 0.73
PiMZ 17/103 1.11 0.64 to 1.93 0.70 15/101 1.52 0.86 to 2.69 0.15
Ever Smokers
PiMM 346/1920 ref. 240/1780 ref.
PiMS 30/152 1.12 0.72 to 1.74 0.62 18/144 0.99 0.58 to 1.66 0.96
PiMZ 9/47 1.20 0.56 to 2.60 0.64 10/43 1.94 0.93 to 4.06 0.08
Persistent Smokersa
PiMM 162/801 ref. 131/705 ref.
PiMS 14/63 0.90 0.46 to 1.78 0.76 8/56 0.76 0.34 to 1.68 0.50
PiMZ 1/17 0.29 0.04 to 2.33 0.25 3/13 1.19 0.31 to 4.56 0.80
Obese Subjectsb
PiMM 94/555 ref. 60/514 ref.
PiMS 6/47 0.63 0.25 to 1.62 0.34 6/43 1.26 0.49 to 3.22 0.63
PiMZ 4/15 1.98 0.57 to 6.83 0.28 4/16 3.24 0.95 to 11.07 0.06
Subjects in upper
tertile of hs-CRPc
PiMM 229/1200 ref. 140/1122 ref.
PiMS 18/88 1.01 0.57 to 1.79 0.96 13/84 1.35 0.71 to 2.56 0.35
PiMZ 7/34 1.04 0.42 to 2.55 0.93 8/32 2.51 1.07 to 5.85 0.03
CI: confidence interval. hs-CRP: high-sensitivity C-reactive protein. OR: odds ratio.
Covariates included sex, linear and squared age, recruiting area, smoking history (packyears at baseline, as well as linear and squared packyears between baseline and
follow-up), height, baseline BMI and BMI change between baseline and follow-up.
aPersistent smokers were classified as subjects who declared current smoking at both examinations.
bObese subjects were defined as BMI$30kg/m2 at the baseline or follow-up examination.
cCorresponded to a level of $ 1.8 mg/l.
doi:10.1371/journal.pone.0042728.t004
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the real effect. Another limitation is the low statistical power for
analyzing obese or persistent smoking PiMZ carriers despite the
large cohort size. Therefore, our findings must be interpreted with
caution. If a correction for multiple testing was applied, none of
the results would remain statistically significant (since all observed
p-values . 0.001). For the same reason, we could neither
distinguish emerging from persistent obesity, nor could we form
strata with enhanced hs-CRP levels of clinical relevance (i.e. 10
mg/l). Finally, the clinical meaning of the observed excess decline
in PiZ heterozygotes could not be reliably estimated, as the
numbers of incident cases with airway obstruction or respiratory
symptoms were too small to investigate differences between
SERPINA1 genotype classes with respect to inflammatory condi-
tions. Nevertheless, we found indication that those subgroups are
more likely to develop respiratory symptoms and we know from
literature that mid expiratory flow rates have been shown to be a
powerful predictor of mortality from COPD, independent of
FEV1 [45].
Conclusion
We confirm in this population-based study that neither PiMS,
nor PiMZ carriers have a substantial impact on longitudinal lung
function. There is indication however, that the presence of one Z
allele may be sufficient to accelerate loss of small airway volume
and incidence of respiratory symptoms in defined population
subgroups which are exposed to pro-inflammatory agents and
conditions. This is a potentially relevant observation as the
prevalence of PiMZ genotype is quite common in Western Europe
[3] and was 2.4% in this study sample. In order to estimate the
public health relevance of our findings, future studies must
associate subgroups of PiMZ individuals to post-bronchodilator
lung function and clinically relevant outcomes like respiratory
symptoms, emphysema by chest computer tomography and
hospitalization for COPD.
Materials and Methods
Ethics Statement
SAPALDIA was approved by the Swiss Academy of Medical
Sciences, the supraregional ethics committee for clinical research
(UREK, Project Approval Number 123/00) and the Cantonal
Ethics Committees for each of the eight examination areas (Ethics
commissions of the cantons Aargau, Basel, Geneva, Grisons,
Ticino, Valais, Vaud and Zurich). Participants were required to
give written consent before any part of the health examination was
conducted either globally (for all health examinations) or
separately for each investigation.
Study Population
In 1991, a random sample of 9651 adults, aged 18-60 years,
from eight areas in Switzerland underwent a detailed health
examination including a questionnaire about respiratory health,
occupational and lifestyle exposures [46]. Participants were
predominantly of European-Caucasian ethnicity and represented
urban and rural areas. Eleven years later, 8047 persons were
reassessed [47]. 6058 follow-up subjects provided blood samples
and consented to DNA analysis. 5274 of these subjects underwent
spirometry testing at baseline and follow-up. Not included in this
analysis were participants with missing smoking history or body
mass index (BMI) data (n = 525), subjects without valid hs-CRP
(n = 18), and subjects for whom genotyping of the S or Z allele
either failed (n = 6) or resulted in PiS homozygosity (n = 10), PiSZ
compound heterozygosity (n = 10) or PiZ homozygosity (n = 1).
Other SERPINA1 rare mutations which lower AAT blood levels
were detected according to a procedure described elsewhere [48]
in additional 29 samples which were also excluded. Our study
sample included thus 4675 subjects.
Measurements
Spirometry was assessed according to American Thoracic
Society criteria using the same spirometers in 1991 and 2002
(Sensormedics model 2200, USA) and by applying stringent
quality control criteria [43]. The forced expiratory manoeuvre
was obtained without bronchodilators. FEV1 and FVC had to
originate from the same manoeuvre in order to provide a valid
FEV1/FVC ratio. Information about the smoking history was
collected by questionnaire. Passive smoking was positive if never
smoking subjects gave an affirmative answer at baseline or follow-
up to the question if they were exposed to environmental tobacco
smoke in the 12 months prior to the examination on most days or
nights. Height and weight were measured and BMI was
calculated as weight divided by squared height. Incident cases
of airflow obstruction were defined as persons with a FEV1/FVC
ratio $ 0.7 at baseline and , 0.7 at follow-up and were
compared to individuals without obstruction at both examina-
tions. Incident cases of respiratory symptoms were defined as
people with self-reported regular cough, phlegm or shortness of
breath at follow-up, but not at baseline. They were compared
with individuals without any of these symptoms at baseline and
follow-up. Cough or phlegm had to be present during the day or
at night on most days for as much as 3 months per year and
shortness of breath had to occur during sleep in the past 12
months before the examination. Subjects who declared an asthma
diagnosis by a physician at baseline or follow-up were defined as
asthmatics.
Serum Analysis
AAT and hs-CRP concentrations were determined from blood
serum aliquots by latex-enhanced immunoturbidimetric assays
(Roche diagnostics, Germany). Lower detection thresholds for the
AAT and CRP assays were 0.21 g/l and 0.1 mg/l, respectively.
Genotyping
Genotyping of SERPINA1 PiS (rs17580) and PiZ (rs28929474)
polymorphisms was carried out using 59 nuclease fluorescent real-
time PCR (TaqMan Probes technology) on LightCycler480
(Roche) as described before [4]. Probes and primers are given in
Table S4. Genotype distributions for PiS and PiZ were both in
Hardy Weinberg equilibrium (p= 0.93, N= 6050, and p=0.99,
N= 6051, respectively).
Statistical Analysis
Statistical tests to evaluate differences in the characteristics
among the different groups of genotype carriers encompassed
Pearson’s x2 for testing equal proportions, analysis of variance
(ANOVA) for testing equal means of normally distributed
continuous data, and Kruskal-Wallis for testing equal distributions
of continuous data which were not normally distributed. Main
effects of SERPINA1 alleles on lung function decline were assessed
using multiple unconditional linear regression models adjusted for
sex, age, recruiting area, smoking history (packyears at baseline
and between baseline and follow-up), height, baseline BMI and
BMI change between baseline and follow-up. Age and packyears
between baseline and follow-up were modeled with linear and
squared terms to better fit to spirometry data. Interactions
between genotypes and other covariates were tested by integrating
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multiplicative terms in the regression models. Two-sided p-values
of ,0.05 (and of ,0.10 for interactions) were considered as
statistically significant. We performed 56 different linear regression
tests (4 respiratory outcomes * 2 genotype comparisons * 7
categories). Bonferroni correction would thus lower the signifi-
cance threshold to p= 0.05/56= 0.001. However, since all
analyses were hypothesis-driven and most tests not independent
of each other, we decided to give the results uncorrected for
multiple testing.
Logistic regression models were used to compare the odds of
developing airflow obstruction or respiratory symptoms between
baseline and follow-up among the SERPINA1 genotype classes.
The models were adjusted for the same covariates mentioned
above. All statistical analyses were performed with STATA,
release 10.1 IC (STATA corporation, USA).
Supporting Information
Table S1 Sensitivity analyses for adjusted mean values
in D(FEV1/FVC) and DFEF25-75% over 11 years of
follow-up comparing different SERPINA1 genotypes.
(PDF)
Table S2 Adjusted mean values in D (FEF25-75%/FVC)
over 11 years of follow-up comparing different SER-
PINA1 genotypes.
(PDF)
Table S3 Adjusted mean values in lung function change
over 11 years of follow-up comparing different SER-
PINA1 genotypes in unweighted and weighted models.
(PDF)
Table S4 Primers and probes for genotyping the
SERPINA1 PiS and PiZ polymorphisms (rs17580 and
rs28929474) using 59 nuclease fluorescent real-time PCR
(TaqMan Probes technology) on LightCycler480 (Roche).
(PDF)
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